How to Afford a GLP-1 Without Insurance (2026)
Educational information only. This article does not diagnose, treat, cure or prevent any condition and is not medical advice. Medication eligibility, cost, and access decisions are a matter for you and your qualified healthcare professional. Program terms change frequently — verify directly with providers before relying on this information.
Brand GLP-1 medications carry a high list price — often around $1,000 or more per month cash-pay in the US. Most people accessing them without insurance coverage use one of three legitimate routes: manufacturer savings programs, cash-pay telehealth programs, or direct-pay clinics. Broadly available compounded versions are no longer a lawful option following the FDA's February 2025 shortage resolution.
Why GLP-1 medications are so expensive without insurance
Semaglutide and tirzepatide are patented medications — no generic equivalent exists as of 2026. The manufacturers set the list price, which in the US is substantially higher than in many other countries due to the structure of the pharmaceutical market. Most insured patients pay far less than list price, but cash-pay patients face the full cost unless they access a savings program or bundled service.
Legitimate routes to lower the cost
1. Manufacturer savings programs
The companies that make Ozempic, Wegovy, Mounjaro and Zepbound offer savings cards and patient assistance programs that can significantly reduce out-of-pocket cost for eligible patients. Eligibility conditions, coverage caps, and terms vary — and they change. Commercial insurance patients are often eligible; those on federal insurance programs like Medicare or Medicaid typically are not. Check the manufacturer's official website for current terms rather than relying on any article, including this one.
2. Cash-pay telehealth programs
A number of telehealth platforms offer GLP-1 prescriptions with bundled pricing — consultation plus medication — at a monthly cost lower than retail list price. Quality and legitimacy vary considerably. Look for platforms that use licensed prescribers and dispense FDA-approved brand medications. Avoid any service that offers compounded semaglutide or tirzepatide at scale — as of 2026, broad compounding of these molecules is not lawful.
3. Direct-pay clinics and obesity medicine specialists
Some obesity medicine practices operate on a direct-pay model and have arrangements that can reduce medication costs for patients, including samples and access to patient assistance programs. The advantage is clinical oversight — these providers can also help with the nutrition, exercise, and supplement support that affects how well the medication works and what you keep after.
What about compounded semaglutide?
For much of 2023–2024, compounded semaglutide was widely available through telehealth platforms while Wegovy and Ozempic were in shortage. The FDA declared the semaglutide shortage resolved in February 2025, after which broad compounding — producing essentially a copy of the brand drug — became impermissible. Only patient-specific, clinically-justified compounding from licensed 503A pharmacies operating within the rules remains permitted. If you're being offered broadly available compounded semaglutide through a telehealth platform in 2026, that is worth scrutinising carefully — see the full article on compounded semaglutide legality for the detail.
Frequently asked
How much do GLP-1 medications cost without insurance?
Brand GLP-1 medications are often priced at around $1,000 or more per month at full list price in the US without insurance or savings programs. Prices vary by region and pharmacy. Manufacturer savings cards and cash-pay telehealth programs can significantly reduce this cost for eligible patients.
Are manufacturer savings programs worth it?
Manufacturer savings programs (sometimes called copay cards or patient assistance programs) can dramatically reduce out-of-pocket costs for eligible patients. Eligibility criteria, coverage caps, and terms vary by manufacturer and change over time — check the manufacturer's official site for current terms.
Is compounded semaglutide still available in 2026?
Broad compounding of semaglutide is no longer permitted following the FDA's declaration that the shortage was resolved in February 2025. Only patient-specific, clinically-justified compounding from licensed 503A pharmacies remains permitted. Broadly available compounded versions are not a legitimate option.
What is a cash-pay telehealth GLP-1 program?
Cash-pay telehealth programs provide prescriptions and sometimes dispensing at a bundled monthly cost, typically lower than paying list price at a retail pharmacy. Quality and legitimacy vary; look for licensed US prescribers and FDA-approved brand medications.
Educational information only. This article does not diagnose, treat, cure or prevent any condition and is not medical advice. Program terms, eligibility, and availability change frequently — verify directly with providers. Always consult a qualified healthcare professional about medication decisions.